Innovative Pharmacotherapy in Alzheimer’s Disease: Facilitating Access as Well as Approval

Michael Murphy, MD, PhD

It’s easy to view the regulatory approval process as the finish line for your new Alzheimer’s therapy. But, beyond clinical safety and efficacy, you need to demonstrate your product’s value proposition to the organizations that facilitate patient access. This new white paper, authored by a group of experts at Worldwide Clinical Trials, discusses considerations and strategies for building a compelling commercial case for a novel Alzheimer’s therapy.

Your form has been successfully submitted! Click the button below to access.
VIEW PDF
Michael Murphy, MD, PhD
MEET THE AUTHOR

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
LEARN MORE